

---

**Invesco Global Health Care Fund**  
Quarterly Schedule of Portfolio Holdings  
January 31, 2017



## Schedule of Investments<sup>(a)</sup>

January 31, 2017

(Unaudited)

|                                                          | Shares    | Value         |
|----------------------------------------------------------|-----------|---------------|
| <b>Common Stocks &amp; Other Equity Interests—96.98%</b> |           |               |
| <b>Biotechnology—37.97%</b>                              |           |               |
| AbbVie Inc.                                              | 335,039   | \$ 20,474,233 |
| ACADIA Pharmaceuticals Inc. <sup>(b)</sup>               | 225,371   | 7,795,583     |
| Alder Biopharmaceuticals, Inc. <sup>(b)</sup>            | 256,668   | 5,274,527     |
| Alexion Pharmaceuticals, Inc. <sup>(b)</sup>             | 147,641   | 19,293,726    |
| Amgen Inc.                                               | 193,526   | 30,321,654    |
| Array BioPharma Inc. <sup>(b)</sup>                      | 1,286,896 | 13,988,559    |
| BioCryst Pharmaceuticals, Inc. <sup>(b)</sup>            | 646,052   | 4,070,128     |
| Biogen Inc. <sup>(b)</sup>                               | 201,323   | 55,814,788    |
| BioMarin Pharmaceutical Inc. <sup>(b)</sup>              | 432,095   | 37,864,485    |
| bluebird bio, Inc. <sup>(b)</sup>                        | 149,755   | 11,156,747    |
| Celgene Corp. <sup>(b)</sup>                             | 740,917   | 86,057,510    |
| DBV Technologies S.A. -ADR (France) <sup>(b)</sup>       | 357,551   | 12,342,661    |
| Evolutionary Genomics, Inc. <sup>(b)</sup>               | 9,944     | 31,324        |
| Exact Sciences Corp. <sup>(b)</sup>                      | 396,463   | 7,512,974     |
| Gilead Sciences, Inc.                                    | 275,056   | 19,927,807    |
| Heron Therapeutics, Inc. <sup>(b)</sup>                  | 391,502   | 5,089,526     |
| Incyte Corp. <sup>(b)</sup>                              | 283,471   | 34,359,520    |
| Neurocrine Biosciences, Inc. <sup>(b)</sup>              | 179,752   | 7,713,158     |
| Prothena Corp. PLC (Ireland) <sup>(b)</sup>              | 170,935   | 8,368,978     |
| REGENXBIO Inc. <sup>(b)</sup>                            | 201,684   | 3,731,154     |
| Sarepta Therapeutics, Inc. <sup>(b)</sup>                | 236,989   | 7,360,878     |
| Shire PLC -ADR                                           | 349,411   | 58,634,660    |
| Spark Therapeutics, Inc. <sup>(b)</sup>                  | 117,138   | 7,386,722     |
| TESARO, Inc. <sup>(b)</sup>                              | 64,934    | 10,573,853    |
| Ultragenyx Pharmaceutical Inc. <sup>(b)</sup>            | 104,950   | 7,872,299     |
| United Therapeutics Corp. <sup>(b)</sup>                 | 57,385    | 9,389,908     |
| Vertex Pharmaceuticals Inc. <sup>(b)</sup>               | 356,194   | 30,586,379    |
|                                                          |           | 522,993,741   |
| <b>Drug Retail—0.51%</b>                                 |           |               |
| Raia Drogasil S.A. (Brazil)                              | 335,078   | 6,970,482     |
| <b>Health Care Distributors—3.03%</b>                    |           |               |
| Cardinal Health, Inc.                                    | 145,630   | 10,916,425    |
| McKesson Corp.                                           | 222,019   | 30,893,944    |
|                                                          |           | 41,810,369    |
| <b>Health Care Equipment—4.66%</b>                       |           |               |
| Olympus Corp. (Japan)                                    | 644,600   | 22,166,518    |
| ResMed Inc.                                              | 196,275   | 13,256,413    |
| Wright Medical Group N.V. <sup>(b)</sup>                 | 1,140,738 | 28,723,783    |
|                                                          |           | 64,146,714    |
| <b>Health Care Facilities—3.60%</b>                      |           |               |
| Brookdale Senior Living Inc. <sup>(b)</sup>              | 472,738   | 7,076,888     |
| HCA Holdings, Inc. <sup>(b)</sup>                        | 255,240   | 20,490,667    |
| Tenet Healthcare Corp. <sup>(b)</sup>                    | 559,127   | 9,835,044     |

|                                                   | Shares  | Value         |
|---------------------------------------------------|---------|---------------|
| <b>Health Care Facilities—(continued)</b>         |         |               |
| Universal Health Services, Inc. -Class B          | 108,703 | \$ 12,243,219 |
|                                                   |         | 49,645,818    |
| <b>Health Care Services—0.77%</b>                 |         |               |
| Envision Healthcare Corp. <sup>(b)</sup>          | 155,110 | 10,547,480    |
| <b>Life Sciences Tools &amp; Services—5.68%</b>   |         |               |
| Agilent Technologies, Inc.                        | 292,823 | 14,339,542    |
| Medpace Holdings, Inc. <sup>(b)</sup>             | 67,573  | 2,357,622     |
| Thermo Fisher Scientific, Inc.                    | 403,752 | 61,527,767    |
|                                                   |         | 78,224,931    |
| <b>Managed Health Care—8.86%</b>                  |         |               |
| Aetna Inc.                                        | 276,897 | 32,842,753    |
| Anthem, Inc.                                      | 94,372  | 14,546,500    |
| HealthEquity, Inc. <sup>(b)</sup>                 | 125,601 | 5,809,046     |
| Humana Inc.                                       | 125,708 | 24,953,038    |
| Qualicorp S.A. (Brazil)                           | 674,900 | 4,417,668     |
| UnitedHealth Group Inc.                           | 243,537 | 39,477,348    |
|                                                   |         | 122,046,353   |
| <b>Pharmaceuticals—31.90%</b>                     |         |               |
| Aclaris Therapeutics, Inc. <sup>(b)</sup>         | 395,505 | 10,492,748    |
| Agile Therapeutics, Inc. <sup>(b)</sup>           | 841,843 | 1,936,239     |
| Allergan PLC <sup>(b)</sup>                       | 137,151 | 30,020,982    |
| AstraZeneca PLC -ADR (United Kingdom)             | 497,340 | 13,542,568    |
| Bayer AG (Germany)                                | 148,559 | 16,406,554    |
| Bristol-Myers Squibb Co.                          | 626,508 | 30,799,133    |
| Dermira, Inc. <sup>(b)</sup>                      | 358,756 | 10,561,777    |
| Eli Lilly and Co.                                 | 517,747 | 39,882,051    |
| Endo International PLC <sup>(b)</sup>             | 719,533 | 8,807,084     |
| Hikma Pharmaceuticals PLC (Jordan)                | 351,148 | 8,057,094     |
| Jazz Pharmaceuticals PLC <sup>(b)</sup>           | 172,512 | 21,032,663    |
| Johnson & Johnson                                 | 127,181 | 14,403,248    |
| Lipocine Inc. <sup>(b)</sup>                      | 722,936 | 2,617,028     |
| Medicines Co. (The) <sup>(b)</sup>                | 124,830 | 4,500,122     |
| Merck & Co., Inc.                                 | 994,061 | 61,621,841    |
| Nippon Shinyaku Co., Ltd. (Japan)                 | 263,000 | 13,575,179    |
| Novartis AG -ADR (Switzerland)                    | 407,230 | 30,102,442    |
| Pfizer Inc.                                       | 447,046 | 14,184,770    |
| Roche Holding AG (Switzerland)                    | 158,569 | 37,369,341    |
| Sanofi -ADR (France)                              | 863,336 | 35,206,842    |
| Supernus Pharmaceuticals Inc. <sup>(b)</sup>      | 352,296 | 9,529,607     |
| Teva Pharmaceutical Industries Ltd. -ADR (Israel) | 610,591 | 20,412,057    |
| Zogenix, Inc. <sup>(b)</sup>                      | 547,363 | 4,406,272     |
|                                                   |         | 439,467,642   |
| Total Common Stocks & Other Equity Interests      |         |               |
| (Cost \$997,446,572)                              |         | 1,335,853,530 |

See accompanying notes which are an integral part of this schedule.

|                                                                                                      | Shares     | Value            |
|------------------------------------------------------------------------------------------------------|------------|------------------|
| <b>Preferred Stock—0.00%</b>                                                                         |            |                  |
| <b>Health Care Equipment—0.00%</b>                                                                   |            |                  |
| Intact Medical Corp., Series C, Pfd.<br>(Acquired 03/26/2001;<br>Cost \$2,000,001) <sup>(c)(d)</sup> |            |                  |
|                                                                                                      | 2,439,026  | \$ 0             |
| <b>Money Market Funds—2.88%</b>                                                                      |            |                  |
| Government & Agency Portfolio                                                                        |            |                  |
| – Institutional Class, 0.47% <sup>(e)</sup>                                                          | 23,847,662 | 23,847,662       |
| Treasury Portfolio                                                                                   |            |                  |
| – Institutional Class, 0.40% <sup>(e)</sup>                                                          | 15,898,442 | 15,898,442       |
| Total Money Market Funds<br>(Cost \$39,746,104)                                                      |            | 39,746,104       |
| TOTAL INVESTMENTS—99.86%<br>(Cost \$1,039,192,677)                                                   |            | 1,375,599,634    |
| OTHER ASSETS LESS LIABILITIES—0.14%                                                                  |            | 1,918,830        |
| NET ASSETS—100.00%                                                                                   |            | \$ 1,377,518,464 |

Investment Abbreviations:

ADR — American Depositary Receipt

Pfd. — Preferred

Notes to Schedule of Investments:

- (a) Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's.
- (b) Non-income producing security.
- (c) Security purchased or received in transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be resold pursuant to an exemption from registration under the 1933 Act, typically to qualified institutional buyers. The value of this security at January 31, 2017 represented less than 1% of the Fund's Net Assets.
- (d) Security is considered venture capital. See Note 1F.
- (e) The money market fund and the Fund are affiliated by having the same investment adviser. The rate shown is the 7-day SEC standardized yield as of January 31, 2017.

See accompanying notes which are an integral part of this schedule.

**Invesco Global Health Care Fund**

## Notes to Quarterly Schedule of Portfolio Holdings

January 31, 2017  
(Unaudited)

### NOTE 1 -- Significant Accounting Policies

#### A. Security Valuations – Securities, including restricted securities, are valued according to the following policy.

A security listed or traded on an exchange (except convertible securities) is valued at its last sales price or official closing price as of the close of the customary trading session on the exchange where the security is principally traded, or lacking any sales or official closing price on a particular day, the security may be valued at the closing bid price on that day. Securities traded in the over-the-counter market are valued based on prices furnished by independent pricing services or market makers. When such securities are valued by an independent pricing service they may be considered fair valued. Futures contracts are valued at the final settlement price set by an exchange on which they are principally traded. Listed options are valued at the mean between the last bid and asked prices from the exchange on which they are principally traded. Options not listed on an exchange are valued by an independent source at the mean between the last bid and asked prices. For purposes of determining net asset value ("NAV") per share, futures and option contracts generally are valued 15 minutes after the close of the customary trading session of the New York Stock Exchange ("NYSE").

Investments in open-end and closed-end registered investment companies that do not trade on an exchange are valued at the end-of-day net asset value per share. Investments in open-end and closed-end registered investment companies that trade on an exchange are valued at the last sales price or official closing price as of the close of the customary trading session on the exchange where the security is principally traded.

Debt obligations (including convertible securities) and unlisted equities are fair valued using an evaluated quote provided by an independent pricing service. Evaluated quotes provided by the pricing service may be determined without exclusive reliance on quoted prices, and may reflect appropriate factors such as institution-size trading in similar groups of securities, developments related to specific securities, dividend rate (for unlisted equities), yield (for debt obligations), quality, type of issue, coupon rate (for debt obligations), maturity (for debt obligations), individual trading characteristics and other market data. Debt obligations are subject to interest rate and credit risks. In addition, all debt obligations involve some risk of default with respect to interest and/or principal payments.

Foreign securities' (including foreign exchange contracts) prices are converted into U.S. dollar amounts using the applicable exchange rates as of the close of the NYSE. If market quotations are available and reliable for foreign exchange-traded equity securities, the securities will be valued at the market quotations. Because trading hours for certain foreign securities end before the close of the NYSE, closing market quotations may become unreliable. If between the time trading ends on a particular security and the close of the customary trading session on the NYSE, events occur that the Adviser determines are significant and make the closing price unreliable, the Fund may fair value the security. If the event is likely to have affected the closing price of the security, the security will be valued at fair value in good faith using procedures approved by the Board of Trustees. Adjustments to closing prices to reflect fair value may also be based on a screening process of an independent pricing service to indicate the degree of certainty, based on historical data, that the closing price in the principal market where a foreign security trades is not the current value as of the close of the NYSE. Foreign securities' prices meeting the approved degree of certainty that the price is not reflective of current value will be priced at the indication of fair value from the independent pricing service. Multiple factors may be considered by the independent pricing service in determining adjustments to reflect fair value and may include information relating to sector indices, American Depositary Receipts and domestic and foreign index futures. Foreign securities may have additional risks including exchange rate changes, potential for sharply devalued currencies and high inflation, political and economic upheaval, the relative lack of issuer information, relatively low market liquidity and the potential lack of strict financial and accounting controls and standards.

Securities for which market prices are not provided by any of the above methods may be valued based upon quotes furnished by independent sources. The last bid price may be used to value equity securities. The mean between the last bid and asked prices is used to value debt obligations, including corporate loans.

Securities for which market quotations are not readily available or became unreliable are valued at fair value as determined in good faith by or under the supervision of the Trust's officers following procedures approved by the Board of Trustees. Issuer specific events, market trends, bid/asked quotes of brokers and information providers and other market data may be reviewed in the course of making a good faith determination of a security's fair value.

The Fund may invest in securities that are subject to interest rate risk, meaning the risk that the prices will generally fall as interest rates rise and, conversely, the prices will generally rise as interest rates fall. Specific securities differ in their sensitivity to

**A. Security Valuations – (continued)**

changes in interest rates depending on their individual characteristics. Changes in interest rates may result in increased market volatility, which may affect the value and/or liquidity of certain Fund investments.

Valuations change in response to many factors including the historical and prospective earnings of the issuer, the value of the issuer's assets, general economic conditions, interest rates, investor perceptions and market liquidity. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

**B. Securities Transactions and Investment Income** – Securities transactions are accounted for on a trade date basis. Realized gains or losses on sales are computed on the basis of specific identification of the securities sold. Interest income (net of withholding tax, if any) is recorded on the accrual basis from settlement date. Dividend income (net of withholding tax, if any) is recorded on the ex-dividend date.

The Fund may periodically participate in litigation related to Fund investments. As such, the Fund may receive proceeds from litigation settlements. Any proceeds received are included in the Statement of Operations as realized gain (loss) for investments no longer held and as unrealized gain (loss) for investments still held.

Brokerage commissions and mark ups are considered transaction costs and are recorded as an increase to the cost basis of securities purchased and/or a reduction of proceeds on a sale of securities. Such transaction costs are included in the determination of net realized and unrealized gain (loss) from investment securities reported in the Statement of Operations and the Statement of Changes in Net Assets and the net realized and unrealized gains (losses) on securities per share in the Financial Highlights. Transaction costs are included in the calculation of the Fund's net asset value and, accordingly, they reduce the Fund's total returns. These transaction costs are not considered operating expenses and are not reflected in net investment income reported in the Statement of Operations and the Statement of Changes in Net Assets, or the net investment income per share and the ratios of expenses and net investment income reported in the Financial Highlights, nor are they limited by any expense limitation arrangements between the Fund and the investment adviser.

The Fund allocates income and realized and unrealized capital gains and losses to a class based on the relative net assets of each class.

**C. Country Determination** – For the purposes of making investment selection decisions and presentation in the Schedule of Investments, the investment adviser may determine the country in which an issuer is located and/or credit risk exposure based on various factors. These factors include the laws of the country under which the issuer is organized, where the issuer maintains a principal office, the country in which the issuer derives 50% or more of its total revenues and the country that has the primary market for the issuer's securities, as well as other criteria. Among the other criteria that may be evaluated for making this determination are the country in which the issuer maintains 50% or more of its assets, the type of security, financial guarantees and enhancements, the nature of the collateral and the sponsor organization. Country of issuer and/or credit risk exposure has been determined to be the United States of America, unless otherwise noted.

**D. Foreign Currency Translations** – Foreign currency is valued at the close of the NYSE based on quotations posted by banks and major currency dealers. Portfolio securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollar amounts at date of valuation. Purchases and sales of portfolio securities (net of foreign taxes withheld on disposition) and income items denominated in foreign currencies are translated into U.S. dollar amounts on the respective dates of such transactions. The Fund does not separately account for the portion of the results of operations resulting from changes in foreign exchange rates on investments and the fluctuations arising from changes in market prices of securities held. The combined results of changes in foreign exchange rates and the fluctuation of market prices on investments (net of estimated foreign tax withholding) are included with the net realized and unrealized gain or loss from investments in the Statement of Operations. Reported net realized foreign currency gains or losses arise from (1) sales of foreign currencies, (2) currency gains or losses realized between the trade and settlement dates on securities transactions, and (3) the difference between the amounts of dividends, interest, and foreign withholding taxes recorded on the Fund's books and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign currency gains and losses arise from changes in the fair values of assets and liabilities, other than investments in securities at fiscal period end, resulting from changes in exchange rates.

The Fund may invest in foreign securities, which may be subject to foreign taxes on income, gains on investments or currency repatriation, a portion of which may be recoverable. Foreign taxes, if any, are recorded based on the tax regulations and rates that exist in the foreign markets in which the Fund invests and are shown in the Statement of Operations.

**E. Forward Foreign Currency Contracts** – The Fund may engage in foreign currency transactions either on a spot (i.e. for prompt delivery and settlement) basis, or through forward foreign currency contracts, to manage or minimize currency or exchange rate risk.

The Fund may also enter into forward foreign currency contracts for the purchase or sale of a security denominated in a foreign currency in order to "lock in" the U.S. dollar price of that security, or the Fund may also enter into forward foreign

#### E. Forward Foreign Currency Contracts – (continued)

currency contracts that do not provide for physical settlement of the two currencies, but instead are settled by a single cash payment calculated as the difference between the agreed upon exchange rate and the spot rate at settlement based upon an agreed upon notional amount (non-deliverable forwards). The Fund will set aside liquid assets in an amount equal to the daily mark-to-market obligation for forward foreign currency contracts.

A forward foreign currency contract is an obligation between two parties (“Counterparties”) to purchase or sell a specific currency for an agreed-upon price at a future date. The use of forward foreign currency contracts does not eliminate fluctuations in the price of the underlying securities the Fund owns or intends to acquire but establishes a rate of exchange in advance. Fluctuations in the value of these contracts are measured by the difference in the contract date and reporting date exchange rates and are recorded as unrealized appreciation (depreciation) until the contracts are closed. When the contracts are closed, realized gains (losses) are recorded. Realized and unrealized gains (losses) on the contracts are included in the Statement of Operations. The primary risks associated with forward foreign currency contracts include failure of the Counterparty to meet the terms of the contract and the value of the foreign currency changing unfavorably. These risks may be in excess of the amounts reflected in the Statement of Assets and Liabilities.

#### F. Other Risks - The Fund's performance is vulnerable to factors affecting the health care industry, including government regulation, obsolescence caused by scientific advances and technological innovations.

The Fund has invested in non-publicly traded companies, some of which are in the startup or development stages. These investments are inherently risky, as the market for the technologies or products these companies are developing are typically in the early stages and may never materialize. The Fund could lose its entire investment in these companies. These investments are valued at fair value as determined in good faith in accordance with procedures approved by the Board of Trustees. Investments in privately held venture capital securities are illiquid.

#### NOTE 2 -- Additional Valuation Information

Generally Accepted Accounting Principles (“GAAP”) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available or are unreliable. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment’s assigned level:

Level 1 – Prices are determined using quoted prices in an active market for identical assets.

Level 2 – Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others.

Level 3 – Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect the Fund’s own assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of January 31, 2017. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

|                                        | Level 1          | Level 2       | Level 3   | Total            |
|----------------------------------------|------------------|---------------|-----------|------------------|
| Common Stocks & Other Equity Interests | \$ 1,262,711,168 | \$ 73,111,038 | \$ 31,324 | \$ 1,335,853,530 |
| Preferred Stock                        | —                | —             | 0         | 0                |
| Money Market Funds                     | 39,746,104       | —             | —         | 39,746,104       |
| Total Investments                      | \$ 1,302,457,272 | \$ 73,111,038 | \$ 31,324 | \$ 1,375,599,634 |

**NOTE 3 -- Investment Securities**

The aggregate amount of investment securities (other than short-term securities, U.S. Treasury obligations and money market funds, if any) purchased and sold by the Fund during the three months ended January 31, 2017 was \$64,025,857 and \$160,567,378, respectively. Cost of investments on a tax basis includes the adjustments for financial reporting purposes as of the most recently completed federal income tax reporting period-end.

**Unrealized Appreciation (Depreciation) of Investment Securities on a Tax Basis**

|                                                              |                |
|--------------------------------------------------------------|----------------|
| Aggregate unrealized appreciation of investment securities   | \$ 410,856,807 |
| Aggregate unrealized (depreciation) of investment securities | (74,780,774)   |
| Net unrealized appreciation of investment securities         | \$ 336,076,033 |

Cost of investments for tax purposes is \$1,039,523,601.